Two drugs for relapsed sarcoma or osteosarcoma
Treatments studied
Part of Cancer clinical trials.
This trial studies a new combination of two drugs, domatinostat and sirolimus, for people with sarcoma or osteosarcoma that hasn't improved after standard treatments. The goal is to see if this combination can help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 12 and 40 years old.
- You must have a sarcoma or osteosarcoma that has come back or hasn't responded to previous treatment.
- You must have tried at least one standard cancer therapy before.
- You need to be able to swallow pills.
- You must not weigh less than 40 kg (about 88 pounds).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, losartan and sunitinib, in people with osteosarcoma that has come back or spread after prior treatment. The study aims to see if this combination is safe and effective.
This trial tests a new drug, HS-20093, combined with other treatments for people with advanced bone or soft tissue sarcoma. The goal is to see if these combinations can shrink tumors or slow their growth.
This Phase 2 trial studies HS-20093 in adults with osteosarcoma or other sarcomas that came back or did not respond to standard treatment. It aims to see how well the drug works and whether it is safe for people whose cancer has progressed.
This trial combines four targeted drugs (gefitinib, trametinib, disulfiram, sunitinib) with standard chemotherapy to treat osteosarcoma that has spread or come back. The goal is to see if this drug mix helps shrink tumors or keep them from growing.
This study tests a combination of two drugs, cabozantinib and ifosfamide, for sarcomas that have come back or not responded to treatment. The goal is to see if this combination can help shrink or control the cancer.
This Phase 2 study tests whether regorafenib, given after your main treatments, can help keep high-grade bone sarcoma from coming back or progressing. It checks safety and whether this “maintenance” approach works better than best supportive care alone.
Hear when a new Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.